[go: up one dir, main page]

MX2023012266A - Un fab anti-tslp con estabilidad mejorada. - Google Patents

Un fab anti-tslp con estabilidad mejorada.

Info

Publication number
MX2023012266A
MX2023012266A MX2023012266A MX2023012266A MX2023012266A MX 2023012266 A MX2023012266 A MX 2023012266A MX 2023012266 A MX2023012266 A MX 2023012266A MX 2023012266 A MX2023012266 A MX 2023012266A MX 2023012266 A MX2023012266 A MX 2023012266A
Authority
MX
Mexico
Prior art keywords
fab
improved stability
tslp
tslp fab
nucleic acids
Prior art date
Application number
MX2023012266A
Other languages
English (en)
Inventor
Emma Suzanne Cohen
Roland Wilhelm Kolbeck
Catherine Eugenie Huntington
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2023012266A publication Critical patent/MX2023012266A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción se refiere a un Fab anti-TSLP con estabilidad mejorada, ácidos nucleicos que codifican dicho Fab, células hospedadoras y vector que comprende dichos ácidos nucleicos, y métodos para usar dicho Fab en el tratamiento de afecciones relacionadas con TSLP.
MX2023012266A 2021-04-19 2022-04-19 Un fab anti-tslp con estabilidad mejorada. MX2023012266A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21169183 2021-04-19
PCT/EP2022/060236 WO2022223514A1 (en) 2021-04-19 2022-04-19 An anti-tslp fab with improved stability

Publications (1)

Publication Number Publication Date
MX2023012266A true MX2023012266A (es) 2023-10-24

Family

ID=75588042

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012266A MX2023012266A (es) 2021-04-19 2022-04-19 Un fab anti-tslp con estabilidad mejorada.

Country Status (19)

Country Link
US (1) US20240199730A1 (es)
EP (1) EP4326767A1 (es)
JP (1) JP2024516962A (es)
KR (1) KR20230172508A (es)
CN (1) CN117222665A (es)
AR (1) AR125379A1 (es)
AU (1) AU2022263281A1 (es)
BR (1) BR112023021587A2 (es)
CA (1) CA3216894A1 (es)
CL (1) CL2023003082A1 (es)
CO (1) CO2023015286A2 (es)
CR (1) CR20230533A (es)
EC (1) ECSP23086870A (es)
IL (1) IL307651A (es)
MX (1) MX2023012266A (es)
PH (1) PH12023552762A1 (es)
SA (1) SA523451188B1 (es)
TW (1) TW202306982A (es)
WO (1) WO2022223514A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE071069T2 (hu) * 2019-10-28 2025-07-28 Medimmune Ltd Tímusz sztrómális limfopoietint (TSLP) kötõ antitestek szárazpor készítményei és eljárások ezek alkalmazására
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2025163008A1 (en) 2024-01-29 2025-08-07 Astrazeneca Ab Compositions of thymic stromal lymphopoietin (tslp) binding fragments and methods of use thereof
WO2025242605A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Inhaler and capsule for delivering thymic stromal lymphopoietin (tslp)-binding antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1340088B1 (en) 2000-11-17 2007-01-17 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
JOP20190243A1 (ar) * 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
WO2021043221A1 (en) * 2019-09-04 2021-03-11 Biosion Inc. Antibodies binding tslp and uses thereof
HUE071069T2 (hu) * 2019-10-28 2025-07-28 Medimmune Ltd Tímusz sztrómális limfopoietint (TSLP) kötõ antitestek szárazpor készítményei és eljárások ezek alkalmazására

Also Published As

Publication number Publication date
CL2023003082A1 (es) 2024-04-19
IL307651A (en) 2023-12-01
WO2022223514A1 (en) 2022-10-27
CN117222665A (zh) 2023-12-12
KR20230172508A (ko) 2023-12-22
SA523451188B1 (ar) 2025-06-22
JP2024516962A (ja) 2024-04-18
US20240199730A1 (en) 2024-06-20
ECSP23086870A (es) 2023-12-29
BR112023021587A2 (pt) 2023-12-19
AR125379A1 (es) 2023-07-12
CO2023015286A2 (es) 2024-02-05
CA3216894A1 (en) 2022-10-27
PH12023552762A1 (en) 2024-04-15
TW202306982A (zh) 2023-02-16
AU2022263281A1 (en) 2023-11-09
AU2022263281A9 (en) 2023-11-16
CR20230533A (es) 2024-04-05
EP4326767A1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
SA523451188B1 (ar) شظية ربط مولد الضد مضادة لـليمفوبويتين الغدة الصعترية ذو ثبات محسن
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
GB2569733A (en) RNA-guided nucleic acid modifying enzymes and methods of use thereof
MX2019003678A (es) Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas.
MY201637A (en) Natural killer cells and ilc3 cells and uses thereof
MX2022003908A (es) Enzimas y aplicaciones de las mismas.
PH12019502331A1 (en) Treatment of asthma with anti-tslp antibody
MX2016001317A (es) Variantes de enzimas.
SA521422495B1 (ar) مستضدات البروستاتا المستحدثة واستخداماتها
AR100606A1 (es) Variantes de lipasas y polinucleótidos que las codifican
EA202190736A1 (ru) Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью
MX2022000425A (es) Metodos y composiciones que comprenden un nivel reducido de proteinas de celulas hospedadoras.
MX2022010514A (es) Metodos de secuenciacion de biopolimeros.
MX2018011980A (es) 3-epimerasa y polinucleotido que la codifica.
WO2016168214A3 (en) Immunogenic fusion proteins for the treatment of cancer
MX388883B (es) Mutaciones en proteinas del grupo hierro-azufre que mejoran la utilizacion de xilosa.
MD20160014A2 (ro) Virus ARN oncolitic stabil genetic, metodă de producere şi de utilizare a acestuia
MY187334A (en) Xylanase
WO2020210480A3 (en) Factor h vectors and uses thereof
CN106687579A8 (zh) 产生二胺的微生物和使用该微生物产生二胺的方法
MY181148A (en) Microorganisms for producing diamine and process for producing diamine using them
WO2015048523A3 (en) Mutant chondroitinase abc i compositions and methods of their use
ZA202001019B (en) Transient silencing of argonaute1 and argonaute4 to increase recombinant protein expression in plants
WO2020185775A3 (en) Materials and methods for reducing nucleic acid degradation in bacteria